Literature DB >> 19276323

Mural Crohn disease: correlation of dynamic contrast-enhanced MR imaging findings with angiogenesis and inflammation at histologic examination--pilot study.

Stuart A Taylor1, Shonit Punwani, Manuel Rodriguez-Justo, Alan Bainbridge, Rebecca Greenhalgh, Enrico De Vita, Alastair Forbes, Richard Cohen, Alastair Windsor, Austin Obichere, Anika Hansmann, Janaki Rajan, Marco Novelli, Steve Halligan.   

Abstract

PURPOSE: To determine mural perfusion dynamics in Crohn disease by using dynamic contrast material-enhanced magnetic resonance (MR) imaging and to correlate these with histopathologic markers of inflammation and angiogenesis.
MATERIALS AND METHODS: Ethical permission was given by the University College London Hospital ethics committee, and informed consent was obtained from all participants. Eleven consecutive patients with Crohn disease (eight female patients, three men; mean age, 39.5 years; range, 16.4-66.6 years) undergoing elective small-bowel resection were recruited between July 2006 and December 2007. Harvey-Bradshaw index, C-reactive protein (CRP) level, and disease chronicity were recorded. Preoperatively, dynamic contrast-enhanced MR imaging was performed through the section of bowel destined for resection, and slope of enhancement, time to maximum enhancement, enhancement ratio, the volume transfer coefficient K(trans), and the extracellular volume fraction v(e) were calculated for the affected segment. Ex vivo surgical specimens were imaged to facilitate imaging-pathologic correlation. Histopathologic sampling of the specimen was performed through the imaged tissue, and microvascular density (MVD) was determined, together with acute and chronic inflammation scores. Correlations between clinical, MR imaging, and histopathologic data were made by using the Kendall rank correlation and linear regression.
RESULTS: Disease chronicity was positively correlated with enhancement ratio (correlation coefficient, 0.82; P = .002). Slope of enhancement demonstrated a significant negative correlation with MVD (correlation coefficient, -0.86; P < .001). There was a negative correlation between CRP level and slope of enhancement (correlation coefficient, -0.77; P = .006). Neither acute nor chronic inflammation score correlated with any other parameter.
CONCLUSION: Certain MR imaging-derived mural hemodynamic parameters correlate with disease chronicity and angiogenesis in Crohn disease, but not with histologic and clinical markers of inflammation. Data support the working hypothesis that microvessel permeability increases with disease chronicity and that tissue MVD is actually inversely related to mural blood flow.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19276323     DOI: 10.1148/radiol.2512081292

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  35 in total

1.  Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study.

Authors:  Alex Menys; David Atkinson; Freddy Odille; Asia Ahmed; Marco Novelli; Manuel Rodriguez-Justo; Ian Proctor; Shonit Punwani; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2012-06-03       Impact factor: 5.315

Review 2.  MRI in Crohn's disease--current and future clinical applications.

Authors:  Gionata Fiorino; Cristiana Bonifacio; Alberto Malesci; Luca Balzarini; Silvio Danese
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-22       Impact factor: 46.802

Review 3.  Assessment of stricturing Crohn's disease: Current clinical practice and future avenues.

Authors:  Dominik Bettenworth; Tobias M Nowacki; Friederike Cordes; Boris Buerke; Frank Lenze
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

4.  Evaluation of Crohn's disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin.

Authors:  Jesica C Makanyanga; Doug Pendsé; Nikolaos Dikaios; Stuart Bloom; Sara McCartney; Emma Helbren; Elaine Atkins; Terry Cuthbertson; Shonit Punwani; Alastair Forbes; Steve Halligan; Stuart A Taylor
Journal:  Eur Radiol       Date:  2013-09-12       Impact factor: 5.315

5.  Quantitative MRI of colonic mural enhancement: segmental differences exist in endoscopically proven normal colon.

Authors:  S Punwani; R Hafeez; A Bainbridge; P Boulos; S Halligan; S Bloom; S A Taylor
Journal:  Br J Radiol       Date:  2012-09       Impact factor: 3.039

Review 6.  Chronic inflammatory diseases of the bowel: diagnosis and follow-up.

Authors:  Guillaume Gorincour; Audrey Aschero; Catherine Desvignes; François Portier; Brigitte Bourlière-Najean; Alix Ruocco-Angari; Philippe Devred; Nathalie Colavolpe; Bertrand Roquelaure; Arnaud Delarue; Philippe Petit
Journal:  Pediatr Radiol       Date:  2010-04-30

7.  Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging.

Authors:  Jordi Rimola; Núria Planell; Sonia Rodríguez; Salvadora Delgado; Ingrid Ordás; Anna Ramírez-Morros; Carmen Ayuso; Montse Aceituno; Elena Ricart; Aranzazu Jauregui-Amezaga; Julián Panés; Míriam Cuatrecasas
Journal:  Am J Gastroenterol       Date:  2015-01-27       Impact factor: 10.864

8.  Intestinal lesions in pediatric Crohn disease: comparative detectability among pulse sequences at MR enterography.

Authors:  Beomseok Sohn; Myung-Joon Kim; Hong Koh; Kyung Hwa Han; Mi-Jung Lee
Journal:  Pediatr Radiol       Date:  2014-03-02

9.  Thalidomide Inhibits Angiogenesis via Downregulation of VEGF and Angiopoietin-2 in Crohn's Disease.

Authors:  Lin Wang; Shengnan Wang; Aijuan Xue; Jieru Shi; Cuifang Zheng; Ying Huang
Journal:  Inflammation       Date:  2020-11-18       Impact factor: 4.092

10.  Assessment of activity of Crohn's disease of the ileum and large bowel: proposal for a new multiparameter MR enterography score.

Authors:  L Macarini; L P Stoppino; A Centola; S Muscarella; F Fortunato; F Coppolino; N Della Valle; V Ierardi; P Milillo; R Vinci
Journal:  Radiol Med       Date:  2012-06-28       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.